Likewise, analysis of AML patient data from the BEAT AML study1, revealed that both CEBPA and GATA2 expression were increased in CEBPANT AML compared to CEBPAWT AML ( + 91% and +37%, respectively), while GATA2 expression was reverted to CEBPAWT level in CEBPANTTET2MUT AML (Supplemental Fig. 5b, c). This evidence concerns the gene CEBPA and acute myeloid leukemia.